EUVIMEDEUVIMED entdecken
Leitlinie

Do all presumed BD-IPMNs require lifelong surveillance? Clinical outcomes and implications of guidelines-based discontinuation

Maria Terrin, Marco Spadaccini, Valeria Poletti, Cataldo De Palma, Miriana Mercurio, Francesco Minini, Matteo Spertino, Matteo Colombo, Marta Andreozzi, Cristiana Bonifacio, Giovanni Capretti, Roberta Elisa Rossi und 5 weitere

Digestive and Liver Disease · 2025-12 · 57 (12) · 2376-2383

DOI: 10.1016/j.dld.2025.10.029 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Digestive and Liver Disease, 2025-12. Verfasst von Maria Terrin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Endoscopic Unit, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano 20089, Milan, Italy. Electronic address: maria.terrin@hum…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Watchful Waiting, Adenocarcinoma, Mucinous. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Management of presumed branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) without worrisome features (WF) or high-risk stigmata (HRS) remains controversial, particularly regarding the duration of surveillance. METHODS: We conducted a retrospective single-center study including patients with presumed BD-IPMNs without WF or HRS at diagnosis, followed between 2014 and 2023. Clinical, radiological, and pathological data were collected. Outcomes included malignant progression, surgery, and mortality. Subgroup analyses assessed patients with ≥5years of follow-up, potentially meeting discontinuation criteria. RESULTS: 413 patients met inclusion criteria. Median age at diagnosis was 65 years; 64 % were women. Median cyst size was 10 mm, and median follow-up 36 months. WF developed in 20 % of patients and HRS in 0.7 %. Four patients (0.26/100 person-years) experienced malignant progression, all within 30 months from diagnosis; two underwent surgery, revealing adenocarcinoma in both. In 108 patients followed ≥5 years, 89 remained stable. None developed cancer, required surgery, or died from BD-IPMN. Seven developed WF after 5 years. Depending on criteria, 49 % according to Marchegiani and 63 % according to Kyoto would qualify for discontinuation of surveillance. CONCLUSIONS: In real-world practice, malignant progression of presumed BD-IPMNs without WF/HRS is rare and tends to occur early. After 5 years of stability, surveillance discontinuation may be safe in selected subgroups, although prospective validation is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalWatchful WaitingAdenocarcinoma, MucinousHumansFemaleAgedRetrospective StudiesMaleMiddle AgedDisease ProgressionPractice Guidelines as TopicAged, 80 and over

Stichwörter der Autor:innen

Branch-Duct Intraductal Papillary Mucinous NeoplasmPancreatic AdenocarcinomaPancreatic Cyst Surveillance

Autor:innen und Institutionen

  • Endoscopic Unit, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano 20089, Milan, Italy. Electronic address: maria.terrin@humanitas.it.
  • Endoscopic Unit, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano 20089, Milan, Italy; Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy; Department of Pancreatic Surgery, IRCCS Humanitas Research Hospital, Rozzano 20089, Milan, Italy.
  • Endoscopic Unit, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano 20089, Milan, Italy.
  • Department of Radiology, IRCCS Humanitas Research Hospital, Rozzano 20089, Milan, Italy.
  • Department of Pancreatic Surgery, IRCCS Humanitas Research Hospital, Rozzano 20089, Milan, Italy.

Zitieren

APA

Terrin, M., Spadaccini, M., Poletti, V., De Palma, C., Mercurio, M., Minini, F., Spertino, M., Colombo, M., Andreozzi, M., Bonifacio, C., Capretti, G., Rossi, R. E., Fugazza, A., Hassan, C., Repici, A., Zerbi, A., & Carrara, S. (2025). Do all presumed BD-IPMNs require lifelong surveillance? Clinical outcomes and implications of guidelines-based discontinuation. Digestive and Liver Disease, 57(12), 2376-2383. https://doi.org/10.1016/j.dld.2025.10.029

Vancouver

Terrin M, Spadaccini M, Poletti V, De Palma C, Mercurio M, Minini F, et al. Do all presumed BD-IPMNs require lifelong surveillance? Clinical outcomes and implications of guidelines-based discontinuation. Digestive and Liver Disease. 2025;57(12):2376-2383. doi:10.1016/j.dld.2025.10.029

BibTeX
@article{Terrin2025,
  author = {Terrin, Maria and Spadaccini, Marco and Poletti, Valeria and De Palma, Cataldo and Mercurio, Miriana and Minini, Francesco and Spertino, Matteo and Colombo, Matteo and Andreozzi, Marta and Bonifacio, Cristiana and Capretti, Giovanni and Rossi, Roberta Elisa and Fugazza, Alessandro and Hassan, Cesare and Repici, Alessandro and Zerbi, Alessandro and Carrara, Silvia},
  title = {Do all presumed BD-IPMNs require lifelong surveillance? Clinical outcomes and implications of guidelines-based discontinuation},
  journal = {Digestive and Liver Disease},
  year = {2025},
  volume = {57},
  number = {12},
  pages = {2376--2383},
  doi = {10.1016/j.dld.2025.10.029}
}
Kostenlos starten →